Barclays Issues Pessimistic Forecast for Kura Oncology (NASDAQ:KURA) Stock Price

Kura Oncology (NASDAQ:KURA - Free Report) had its price target reduced by Barclays from $32.00 to $11.00 in a research note published on Friday,Benzinga reports. They currently have an overweight rating on the stock.

Several other brokerages have also issued reports on KURA. Wedbush reiterated an "outperform" rating and issued a $36.00 price target on shares of Kura Oncology in a report on Tuesday, April 8th. JMP Securities reiterated a "market outperform" rating and set a $28.00 price target on shares of Kura Oncology in a report on Tuesday, April 29th. Scotiabank cut their price objective on shares of Kura Oncology from $18.00 to $10.00 and set a "sector perform" rating on the stock in a report on Wednesday, January 8th. Cantor Fitzgerald upgraded shares of Kura Oncology to a "strong-buy" rating in a report on Tuesday, March 4th. Finally, BTIG Research lowered shares of Kura Oncology from a "buy" rating to a "neutral" rating in a research note on Thursday, February 6th. Four equities research analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have given a strong buy rating to the company's stock. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $23.89.

Kura Oncology Trading Down 1.8 %

KURA traded down $0.10 during trading on Friday, reaching $5.69. 880,013 shares of the stock traded hands, compared to its average volume of 1,162,995. The stock's 50-day moving average is $6.67 and its 200 day moving average is $9.42. Kura Oncology has a 12 month low of $5.41 and a 12 month high of $23.48. The company has a quick ratio of 11.47, a current ratio of 11.47 and a debt-to-equity ratio of 0.02. The stock has a market capitalization of $459.30 million, a PE ratio of -2.42 and a beta of 0.50.

Kura Oncology (NASDAQ:KURA - Get Free Report) last released its quarterly earnings data on Thursday, May 1st. The company reported ($0.66) earnings per share for the quarter, missing the consensus estimate of ($0.51) by ($0.15). The firm had revenue of $14.11 million for the quarter, compared to the consensus estimate of $39.08 million. Equities analysts anticipate that Kura Oncology will post -2.44 earnings per share for the current year.

Institutional Investors Weigh In On Kura Oncology

Large investors have recently added to or reduced their stakes in the company. Barclays PLC lifted its stake in shares of Kura Oncology by 104.5% during the 3rd quarter. Barclays PLC now owns 165,484 shares of the company's stock valued at $3,234,000 after buying an additional 84,563 shares in the last quarter. Franklin Resources Inc. lifted its position in shares of Kura Oncology by 1.5% during the third quarter. Franklin Resources Inc. now owns 1,588,401 shares of the company's stock worth $28,687,000 after acquiring an additional 23,113 shares in the last quarter. JPMorgan Chase & Co. boosted its holdings in shares of Kura Oncology by 0.8% in the third quarter. JPMorgan Chase & Co. now owns 409,241 shares of the company's stock worth $7,997,000 after acquiring an additional 3,092 shares during the period. Harbor Capital Advisors Inc. grew its position in shares of Kura Oncology by 4.4% in the fourth quarter. Harbor Capital Advisors Inc. now owns 49,371 shares of the company's stock valued at $430,000 after purchasing an additional 2,076 shares in the last quarter. Finally, SG Americas Securities LLC bought a new stake in shares of Kura Oncology during the 4th quarter valued at $436,000.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.